Wells Fargo & Company Veracyte, Inc. Transaction History

Wells Fargo & Company

$433 Billion
Q4 2024

A detailed history of Wells Fargo & Company transactions in Veracyte, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 51,131 shares of VCYT stock, worth $2.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,131

Previous 39,744 28.65%

Holding current value

$2.1 Million

Previous $1.35 Million 49.7%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$31.92 - $44.4 $363,473 - $505,582	11,387 Added 28.65%	51,131 $2.02 Million
Q3 2024 Nov 13, 2024	SELL	$21.0 - $35.25 $1.12 Million - $1.88 Million	-53,315 Reduced 57.29%	39,744 $1.35 Million
Q2 2024 Aug 13, 2024	SELL	$18.86 - $23.55 $62,539 - $78,091	-3,316 Reduced 3.44%	93,059 $2.02 Million
Q1 2024 May 10, 2024	BUY	$21.0 - $29.1 $296,415 - $410,746	14,115 Added 17.16%	96,375 $2.14 Million
Q4 2023 Feb 09, 2024	SELL	$19.72 - $28.68 $657,346 - $956,019	-33,334 Reduced 28.84%	82,260 $2.26 Million
Q3 2023 Nov 13, 2023	SELL	$22.33 - $29.92 $376,640 - $504,660	-16,867 Reduced 12.73%	115,594 $2.58 Million
Q2 2023 Aug 15, 2023	BUY	$20.96 - $26.99 $150,974 - $194,408	7,203 Added 5.75%	132,461 $3.37 Million
Q1 2023 May 12, 2023	BUY	$20.58 - $27.89 $1.23 Million - $1.67 Million	60,007 Added 91.96%	125,258 $2.79 Million
Q4 2022 Feb 13, 2023	SELL	$15.31 - $29.94 $103,694 - $202,783	-6,773 Reduced 9.4%	65,251 $1.55 Million
Q3 2022 Nov 14, 2022	SELL	$16.58 - $27.9 $68,657 - $115,533	-4,141 Reduced 5.44%	72,024 $1.2 Million
Q2 2022 Aug 12, 2022	SELL	$15.45 - $29.52 $758,965 - $1.45 Million	-49,124 Reduced 39.21%	76,165 $1.52 Million
Q1 2022 May 16, 2022	SELL	$21.94 - $42.51 $271,529 - $526,103	-12,376 Reduced 8.99%	125,289 $3.45 Million
Q4 2021 Feb 14, 2022	SELL	$36.09 - $53.79 $1.92 Million - $2.86 Million	-53,135 Reduced 27.85%	137,665 $5.67 Million
Q3 2021 Nov 15, 2021	BUY	$35.62 - $52.97 $69,565 - $103,450	1,953 Added 1.03%	190,800 $8.86 Million
Q2 2021 Aug 16, 2021	SELL	$32.94 - $56.62 $618,580 - $1.06 Million	-18,779 Reduced 9.04%	188,847 $7.55 Million
Q1 2021 May 13, 2021	BUY	$44.47 - $81.38 $610,528 - $1.12 Million	13,729 Added 7.08%	207,626 $11.2 Million
Q4 2020 Feb 09, 2021	SELL	$32.49 - $61.88 $1.32 Million - $2.51 Million	-40,612 Reduced 17.32%	193,897 $9.49 Million
Q3 2020 Nov 05, 2020	SELL	$26.73 - $35.67 $201,998 - $269,558	-7,557 Reduced 3.12%	234,509 $7.62 Million
Q2 2020 Aug 13, 2020	BUY	$19.49 - $28.11 $184,375 - $265,920	9,460 Added 4.07%	242,066 $6.27 Million
Q1 2020 May 14, 2020	BUY	$16.13 - $30.17 $3.75 Million - $7.02 Million	232,606 New	232,606 $5.66 Million

Others Institutions Holding VCYT

# of Institutions

336

Shares Held

80M

Call Options Held

212K

Put Options Held

18.5K

View Full List

About VERACYTE, INC.

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.94B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

More about VCYT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Veracyte, Inc. Transaction History